newsfilter
← Latest News
FDA Press Releases·

FDA Launches New Program to Advance Neuroscience Medical Product Development

  • The U.S. Food and Drug Administration launched the Neuroscience Advancement and Innovation Nexus (NAIN) on October 22, 2026, aligning with the Trump Administration's goals to accelerate medical innovation.
  • NAIN aims to advance science, tools, & regulatory approaches for medical products targeting brain & nervous system conditions.
  • The program's inaugural initiative is the Alzheimer's Prevention Accelerator, which focuses on products designed to delay or prevent Alzheimer's disease.
  • Both NAIN & the Accelerator support the National Alzheimer's Project Act (NAPA), the federal roadmap for coordinated action on Alzheimer's & related dementias.
  • Acting FDA Commissioner Kyle Diamantas stated the launch reflects a commitment to ensuring regulatory science & cross-center collaboration keep pace with neuroscience advances.
  • Developing neuroscience products involves complex challenges like limited biological understanding, variable disease presentation, & difficulties in proving clinical benefit over long periods.
  • NAIN will integrate expertise from the Centers for Drug Evaluation & Research, Biologics Evaluation & Research, & Devices and Radiological Health to address questions across drugs, biologics, & devices.
  • The program covers a broad range of conditions including neurologic & psychiatric disorders, substance use disorders, & pain.
  • NAIN will foster engagement with patients, industry, academia, & other stakeholders to advance its efforts.
  • The Alzheimer's Prevention Accelerator will explore innovative clinical trial approaches focusing on trial populations, stage-appropriate endpoints, & evidentiary methods for demonstrating prevention or delay of cognitive decline.
  • The FDA is taking a proactive, coordinated approach to accelerate progress on brain & nervous system diseases by leveraging its scientific expertise & partnering with federal agencies.